

CDK4 Antibody

Catalog No: #32073

Package Size: #32073-1 50ul #32073-2 100ul


Description

Product Name	CDK4 Antibody
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Affinity purification
Applications	WB,IHC
Species Reactivity	Human,Mouse,Rat
Specificity	The antibody detects endogenous level of total CDK4 protein.
Immunogen Type	Peptide
Immunogen Description	Recombinant fusion protein of human CDK4 (NP_000066.1).
Conjugates	Unconjugated
Target Name	CDK4
Other Names	CDK4;CMM3;PSK-J3
Accession No.	Uniprot:P11802GeneID:1019
SDS-PAGE MW	34kDa
Concentration	1.0mg/ml
Formulation	PBS with 0.02% sodium azide,50% glycerol,pH7.3.
Storage	Store at -20°C. Avoid freeze / thaw cycles.


Application Details

WB 1:500 - 1:2000IHC 1:50 - 1:200


Images



Western blot analysis of extracts of various cell lines, using CDK4 antibody.



Western blot analysis of extracts of various cell lines, using CDK4 antibody.



Immunohistochemistry of paraffin-embedded human colon using CDK4 antibody.

Background

The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of *S. cerevisiae* *cdc28* and *S. pombe* *cdc2*. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported.

Published Papers

el at., Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27. In *Cell Cycle* on

2021 Dec 16 by Katia Coulonval, Vincent Vercruysse, et al..PMID:34913830, , (2021)

[PMID:34913830](#)

el at., CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways. In *Cancers (Basel)* on 2022 Nov 15 by Xiyang Tan, Jie Yang, et al..PMID:36428703, , (2022)

[PMID:36428703](#)

Zhipeng Zhang;Yanmei Wu;Wenqiang Liang;Zhifang Liao;Hongbo Liao;Xingxing Xing;Wenxin Yi;Zixuan Liu;Yicheng Li;Mengya Shi;Dongling Lin;Ting Gu;Biao Wu;Mingzhi Zou;Huilai Miao;Xin Wu el at., Eurycomalactone switched hepatocellular carcinoma cells into quiescence through 5'IRFAla/DVL/β-catenin pathway inhibition., , (2025)

[PMID:40128187](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.